Dominick C. Colangelo, CEO
Mr. Colangelo joined Promedior in December 2008 with 15 years of pharmaceutical industry experience, including nearly a decade with Eli Lilly and Company. During his career, Mr. Colangelo has held a variety of executive positions of increasing responsibility in finance, product development, pharmaceutical operations, and corporate business development. During his tenure at Eli Lilly and Company, Mr. Colangelo held positions as an international tax attorney in the finance organization and as Director of Strategy and Business Development for Lilly’s Diabetes and Growth Disorders Product Group. He also served as a founding Managing Director of Lilly Ventures. Mr. Colangelo received a B.S.B.A. degree in Accounting from the State University of New York at Buffalo and a J.D. degree from the Duke University School of Law.
Mark L. Lupher, Jr., Ph.D., Sr. Vice President of Drug Discovery
Dr. Lupher has wide-ranging experience in the discovery and development of both biologic and small molecule drug candidates for the treatment of inflammatory and fibrotic diseases. As Associate Director of Drug Discovery at ICOS Corporation, he pioneered the discovery of novel anti-fibrotic therapeutics and the development of the fibrotic disease therapeutic area. In addition, Dr. Lupher was responsible for a new Evaluation and Alliance group within Research to initiate and manage research licensing and collaborations with peer biotechnology companies. Dr. Lupher has held various R&D positions at biopharmaceutical companies such as ICOS Corporation and Immunex. Dr. Lupher holds a Ph.D. in Immunology from the Division of Medical Sciences at Harvard University and was a Post-Doctoral fellow at the Brigham and Women's Hospital.
John A. Getsy, D.M.D., D.O., VICE PRESIDENT OF Clinical Research and Development
Dr. Getsy has extensive experience in clinical pharmacology, experimental and translational medicine, and clinical drug development of biologics and small molecules and was pivotal in the filings of several NDA’s and BLA’s. He has developed drugs in multiple therapeutic areas including : immunology, transplant, CNS, ophthalmology, dermatology, cardiovascular, metabolism, allergy/immunology, and pulmonary therapeutic areas. In his most recent position at Centocor, he was head of the clinical pharmacology trial design and management and the experimental and translational medicine groups. Dr. Getsy holds a D.M.D. degree from Temple University and his medical degree from Des Moines University. He is boarded in internal medicine, rheumatology, and clinical pharmacology.
W. Scott Willett, Ph.D., Sr. Director, Biopharmaceutical Development
Dr. Willett has 14 years of experience in the biopharmaceutical industry in development of protein purification processes for recombinant therapeutics. Prior to Promedior, Dr. Willett served as Director of Process Development at Neose Technologies, leading development and technology transfer for Phase I clinical manufacture of GlycoPEGylation™ processes for improved protein therapeutics. Before joining Neose, Dr. Willett was a Process Development Scientist at Amgen, Thousand Oaks, where he led teams in development of Phase I cGMP purification processes for several proteins, in addition to supporting Amgen’s commercial products. Dr. Willett holds a Ph.D. in Pharmaceutical Chemistry from the University of California at San Francisco, and was an NSF Post-doctoral Fellow at the University of Colorado at Boulder. He also earned a Bachelor of Science degree in Chemical Engineering from the University of Michigan at Ann Arbor.